Evidence map›Paper›PMID 38772903›Full record

ReviewAmerican journal of physiology. Lung cellular and molecular physiology2024

Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023.

Robert E Hynds, Chelsea M Magin, Laertis Ikonomou, Yael Aschner, Michael F Beers, Janette K Burgess, Rebecca L Heise, Patrick S Hume, Anna D Krasnodembskaya, Shirley H J Mei and 10 more

Abstract readReview
In one paragraph

Review in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Engineering function in lung biology: integrating imaging, regenerative constructs, and functional biodesign.American journal of physiology. Lung cellular and molecular physiology · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Robert E HyndsEpithelial Cell Biology in ENT Research Group, Developmental Biology and Cancer Department, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.ORCID 0000-0002-2170-8791
Chelsea M MaginDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.ORCID 0000-0002-6988-8584
Laertis IkonomouDepartment of Oral Biology, University at Buffalo, State University of New York, Buffalo, New York, United States.ORCID 0000-0003-0993-6713
Yael AschnerDivision of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.ORCID 0000-0002-8246-1083
Michael F BeersPulmonary, Allergy, and Critical Care Division, Department of Medicine and PENN-CHOP Lung Biology Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States.ORCID 0000-0002-2149-3209
Janette K BurgessDepartment of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0001-9868-9966
Rebecca L HeiseDepartment of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia, United States.ORCID 0000-0002-6602-6700
Patrick S HumeDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado, United States.ORCID 0000-0002-5861-7375
Anna D KrasnodembskayaWellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.ORCID 0000-0002-2380-5069
Shirley H J MeiRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0003-4727-1177
Alexander V MisharinDivision of Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States.
Jin-Ah ParkDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, United States.ORCID 0000-0002-8930-9287
Susan D ReynoldsCenter for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Daniel J TschumperlinDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States.ORCID 0000-0002-5115-9025
Alicia E TannebergerDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.
Sriram VaidyanathanCenter for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Christopher M WatersDepartment of Physiology and Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States.ORCID 0000-0002-6706-1284
Patricia J ZettlerMoritz College of Law, Drug Enforcement and Policy Center, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States.
Daniel J WeissDepartment of Medicine, University of Vermont, Burlington, Vermont, United States.
Amy L RyanDepartment of Anatomy and Cell Biology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States.ORCID 0000-0003-1363-905X

Funding

Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
Alveolar Epithelial Cell Dysfunction in Pulmonary Fibrosis: Leveraging SFTPC Mutations for Discovery of Molecular and Cellular TargetsR01HL145408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MICHAEL FRANCIS BEERS · 2019 to 2026
$4.6M
Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary FibrosisU01HL152970 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BEERS, MICHAEL FRANCIS · 2021 to 2024
$3.0M
Interstitial macrophages in cigarette smoke-induced small airway remodelingK08HL155894 · NHLBI · NATIONAL JEWISH HEALTH · PI Patrick Scott Hume · 2022 to 2026
$792k
Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung DiseasesR13HL170688 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI RYAN, AMY LEANNE, WEISS, DANIEL J · 2023 to 2023
$35k
Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung DiseasesR13HL160043 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI RYAN, AMY LEANNE, WEISS, DANIEL J · 2021 to 2021
$30k
Company of Biologists N/ACystic Fibrosis Foundation (CFF) N/AHHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R13HL170688International Society for Cell Therapy N/ANational Science Foundation (NSF) 2327935NHLBI NIH HHS K08 HL155894NHLBI NIH HHS R01 HL145408NHLBI NIH HHS R13 HL160043NHLBI NIH HHS R13 HL170688NHLBI NIH HHS U01 HL152970NIDDK NIH HHS P30 DK054759Pulmonary Fibrosis Foundation (PFF) 1029996Roche Holding | Genentech (Genentech USA) N/AUnited Therapeutics Corporation (United Therapeutics) N/A
6 · The paper itself

Abstract

Repair and regeneration of a diseased lung using stem cells or bioengineered tissues is an exciting therapeutic approach for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence from preclinical models suggests that mesenchymal stromal cells, which are not normally resident in the lung, can be used to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating the use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those involving stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in our understanding of the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise during lung development and participate in normal and pathological remodeling after lung injury. For the 2023 Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference, scientific symposia were chosen to reflect the most cutting-edge advances in these fields. Sessions focused on the integration of "omics" technologies with function, the influence of immune cells on regeneration, and the role of the extracellular matrix in regeneration. The necessity for basic science studies to enhance fundamental understanding of lung regeneration and to design innovative translational studies was reinforced throughout the conference.

Indexed as

BioengineeringLungLung DiseasesAnimalsCell- and Tissue-Based TherapyHumansRegenerationStem CellsStem Cell TransplantationTissue Engineeringairway epitheliumalveolar epitheliumextracellular matriximmune cellslung regeneration

Identifiers

PMID38772903
PMCPMC11442098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.